Announcements
- Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform
- Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference
- Certara Reports Fourth Quarter 2023 Financial Results
- Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference
- Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies
- Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development
- Certara Reports Third Quarter 2023 Financial Results
- Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment Conference
- Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software
- Certara to Participate in Upcoming Investor Conferences
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 288.06 |
Average volume | 0.00 |
---|---|
Shares outstanding | 160.19m |
Free float | 119.16m |
P/E (TTM) | -- |
Market cap | 2.60bn USD |
EPS (TTM) | -0.3478 USD |
Data delayed at least 20 minutes, as of Sep 06 2022 12:30 BST.
More ▼